Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs

被引:50
|
作者
Patel, Kush K. K. [1 ]
Kashfi, Khosrow [1 ,2 ]
机构
[1] CUNY, Sch Med, Sophie Davis Sch Biomed Educ, Dept Mol Cellular & Biomed Sci, New York, NY 10031 USA
[2] CUNY, Grad Ctr, Grad Program Biol, New York, NY USA
基金
美国国家卫生研究院;
关键词
Cholesterol; HDL-C; LDL-C; HMG-CoA reductase; Statins; SREBP-2; DIFFERENTIALLY EXPRESSED PROTEINS; REGULATED METABOLIC PATHWAYS; INHIBIT TUMOR-DEVELOPMENT; LOW-DENSITY-LIPOPROTEIN; HMG-COA REDUCTASE; PROSTATE-CANCER; COLORECTAL-CANCER; NITRIC-OXIDE; SIGNALING PATHWAY; MUTANT P53;
D O I
10.1016/j.bcp.2021.114654
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cholesterol is an amphipathic sterol molecule that is vital for maintaining normal physiological homeostasis. It is a relatively complicated molecule with 27 carbons whose synthesis starts with 2-carbon units. This in itself signifies the importance of this molecule. Cholesterol serves as a precursor for vitamin D, bile acids, and hormones, including estrogens, androgens, progestogens, and corticosteroids.Although essential, high cholesterol levels are associated with cardiovascular and kidney diseases and cancer initiation, progression, and metastasis. Although there are some contrary reports, current literature suggests a positive association between serum cholesterol levels and the risk and extent of cancer development. In this review, we first present a brief overview of cholesterol biosynthesis and its transport, then elucidate the role of cholesterol in the progression of some cancers. Suggested mechanisms for cholesterol-mediated cancer progression are plentiful and include the activation of oncogenic signaling pathways and the induction of oxidative stress, among others. The specific roles of the lipoprotein molecules, high-density lipoprotein (HDL) and low-density lipoprotein (LDL), in this pathogenesis, are also reviewed. Finally, we hone on the potential role of some cholesterol-lowering medications in cancer.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Association of LDL-C/HDL-C Ratio With Hyperuricemia: A National Cohort Study
    Zhang, Yanyu
    Liu, Xiaoyi
    Luo, Deyun
    Chen, Bingli
    Lai, Chenyi
    He, Chenyu
    Yan, Luo
    Ding, Haifeng
    Li, Shiyang
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (01):
  • [22] LDL-C/HDL-C RATIO PREDICTS IMT PROGRESSION MORE THAN HDL-C OR LDL-C ALONE: 8-YEAR FOLLOW-UP STUDY IN A GENERAL POPULATION
    Enomoto, M.
    Adachi, H.
    Satoh, A.
    Fukami, A.
    Otsuka, M.
    Kumagae, S.
    Furuki, K.
    Nanjo, Y.
    Kumagai, E.
    Esaki, E.
    Murayama, K.
    Hirai, Y.
    Imaizumi, T.
    JOURNAL OF HYPERTENSION, 2009, 27 : S104 - S104
  • [23] LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study
    Jukema, JW
    Liem, AH
    Dunselman, PHJM
    van der Sloot, JAP
    Lok, DJA
    Zwinderman, AH
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (11) : 1865 - 1874
  • [24] PLASMA-LEVELS OF CHOLESTEROL (C), HDL-C, LDL-C AND TRIGLYCERIDES (TG) IN RENAL TRANSPLANTED PATIENTS TREATED WITH CSA
    SEGARRA, A
    VILA, J
    CAPDEVILA, L
    CHACON, P
    VILARDELL, M
    PIERA, L
    KIDNEY INTERNATIONAL, 1991, 40 (02) : 360 - 360
  • [25] BARIATRIC SURGERY IMPROVES LIPID PROFILE IN MORBIDLY OBESE PATIENTS BY LOWERING LDL-C AND INCREASING HDL-C AND THE LARGE HDL-PARTICLES
    Kjellmo, C. A.
    Nestvold, T.
    Lappegard, K. T.
    Hovland, A.
    Mathisen, M.
    ATHEROSCLEROSIS, 2016, 252 : E142 - E143
  • [26] New and Emerging LDL Cholesterol-Lowering Drugs
    Kosmas, Constantine E.
    Frishman, William H.
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (03) : 234 - 241
  • [27] LDL-C/HDL-C及TG/HDL-C比值对冠心病的预测价值的评价
    刘梅颜
    郭丹杰
    胡大一
    徐成斌
    崔永东
    中国医刊, 2002, (05) : 33 - 35
  • [28] LDL-C/HDL-C异常对脑梗死预后的影响
    王亚琴
    戴其军
    中国现代药物应用, 2008, (13) : 64 - 65
  • [29] Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes
    Brunzell, J
    Cohen, BR
    Kreider, M
    Biswas, N
    Ratner, RE
    Freed, MI
    Marcovina, S
    DIABETES, 2001, 50 : A141 - A141
  • [30] The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C
    Teramoto, Tamio
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (06) : 859 - 865